Literature DB >> 33338852

Immunological landscape of Neuroblastoma and its clinical significance.

Sai Batchu1.   

Abstract

Immune infiltration in neuroblastoma (NBL) has been associated with clinical outcome. However, the diversity of distinct immune subpopulations that comprise immune infiltrates in NBL has not been examined. To this end, the present study investigated the immunological landscape of NBL tumors and its clinical significance. CIBERSORTx, an established RNA deconvolution algorithm, was used to impute immune cell proportions from 153 primary NBL tumors. Associations between immune proportions and overall/event-free survival were analyzed by Kaplan-Meier curves and evaluated using log-rank test. Of the 22 subpopulations imputed, M2 macrophages were the most abundant subtype in NBL tumors. Furthermore, monocytes, CD4+ naïve T cells, and CD4+ activated memory T cells were significantly associated with survival. Altogether, the findings suggest differences amongst certain immune cell subsets comprising NBL tumor infiltration and these differences may be important determinants of prognosis.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  Immunological landscape; Neuroblastoma; Rna deconvolution; Tumor-infiltrating immune cells

Mesh:

Year:  2020        PMID: 33338852     DOI: 10.1016/j.ctarc.2020.100274

Source DB:  PubMed          Journal:  Cancer Treat Res Commun        ISSN: 2468-2942


  2 in total

1.  Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology.

Authors:  Bharati Mehani; Saleembhasha Asanigari; Hye-Jung Chung; Karen Dazelle; Arashdeep Singh; Sridhar Hannenhalli; Kenneth Aldape
Journal:  Acta Neuropathol Commun       Date:  2022-02-10       Impact factor: 7.801

2.  Development of a prognostic model for children with neuroblastoma based on necroptosis-related genes.

Authors: 
Journal:  Front Genet       Date:  2022-08-05       Impact factor: 4.772

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.